Search tips
Search criteria 


Logo of bactLink to Publisher's site
Bacteriophage. 2011 July 1; 1(4): 195–197.
PMCID: PMC3448104

Phage as a source of antibacterial genes

Multiple inhibitory products encoded by Rhodococcus phage YF1


Bacteriophage-encoded proteins which inhibit or modify cellular components may contribute to antibacterial drug discovery by allowing the identification of novel targets. Given their abundance and diversity, phages may have various strategies in host inhibition and therefore may possess a variety of such proteins. Using Rhodococcus equi and phage YF1, we show that a single phage possesses numerous genes that inhibit the host when introduced into the host on a plasmid. These genes mostly encode proteins of unknown function, confirming the potential that this approach may have in providing new antibacterial targets.

Keywords: antibacterial drug discovery, bactericidal proteins, multidrug resistance, phage YF1, target identification

Bacteriophages encode early proteins that may alter or inactivate indispensable host proteins upon infection.1 In an effort to combat multidrug resistance in bacterial pathogens, these host proteins might serve as novel targets in antibacterial drug discovery. This approach was demonstrated by the work of Liu et al.,2 who identified both phage polypeptides and their cellular targets in Staphylococcus aureus, as well as small molecules which could bind the cellular targets and inhibit the pathogen. As interactions of phage proteins with their targets are expected to be essential for phages to engage in their lytic cycle, effective antibacterials might be discovered through this method. Considering phage abundance in the environment and their tremendous diversity,3 there should be an existent phage and therefore an existent strategy to combat any given bacterial pathogen, so exploration of the strategy reported has yet to meet its full potential. In this work we focused on Rhodococcus equi,4 a Gram-positive, pulmonary, intracellular pathogen of foals and AIDS patients, as a model to demonstrate that a phage infecting this pathogen can be used to elucidate a number of potential targets for the development of antimicrobial products. Although R. equi is a rarely encountered human opportunistic pathogen, its close relation to significant pathogens from genera such as Mycobacterium and Corynebacterium and the emergence of multidrug resistant strains5 place this species in an ideal framework for antimicrobial drug discovery.

As the rhodococci are ubiquitous soil saprophytes, we first isolated from soil a phage plaquing on R. equi ATCC 14887. On a lawn of the host bacteria, a single soil sample incubated in rich broth yielded plaques of various sizes and morphologies, one of which was plaque purified and now named YF1. Observation of purified, negatively-stained YF1 particles under the electron microscope revealed a head-and-tail structure of the Siphoviridae family (Fig. 1A). Besides R. equi, the phage was capable of plaquing on Rhodococcus erythropolis ATCC 4277, Rhodococcus rhodochrous Ri8, and Rhodococcus opacus HL PM-1 at efficiencies of plaquing of 1.0, 0.8, and 0.1, respectively, but not on Gordonia australis A554, Gordonia rubropertincta ATCC 25593, Gordonia desulphuricans NB4, Nocardia mexicana IFO 3927, Mycobacterium smegmatis mc2155, or Mycobacterium parafortuitum IFM 0490. The YF1 genome size was estimated to be 55 kb using pulsed-field electrophoresis (Fig. 1B).

figure bact-1-195-g1
Figure 1. Phage YF1 characteristics. (A) Electron micrograph of negatively stained phage YF1 (bar = 100 nm), (B) pulsed-field gel electrophoresis of YF1 genome, and (C) restriction digests of YF1 genomic DNA. Lane 1, molecular weight marker; 2, undigested ...

Two genomic libraries of YF1 were constructed in Escherichia coli by shotgun-cloning of BglII and PstI digests separately into the E. coli-Rhodococcus shuttle vector pDA71,6 which is a fusion of E. coli vector pEcoR251 and the replicon from a Rhodococcus phage Q4, and has a low copy-number in Rhodococcus. The polylinker of pDA71 is flanked on one end with the phage λ PR promoter. Enzymes BglII and PstI have recognition sites in this polylinker and also generated many YF1 DNA fragments in the size range of 1–6 kb upon complete digestion (Fig. 1C); thus they were deemed suitable for library construction. The first library consisted of 140 clones of BglII digests, with an average insert size per clone of 2.5 kb and covering 99% of the genome, calculated using an equation described by Clarke and Carbon.7 Upon screening 20 clones, 85% of them had detectable inserts. The second library consisted of 95 clones of PstI digests, with an average insert size per clone of 2.7 kb and also covering 99% of the genome. Upon screening 20 of these clones, 80% of them had detectable inserts. Twenty randomly-selected clones from each library, representing roughly 60% coverage of the YF1 genome in the case of the BglII library and 63% in the case of the PstI library, were screened for an inhibitory phenotype by transforming them into R. equi in triplicate. Six clones from the BglII library and nine clones from the PstI library were shown to have transformation efficiencies of at least two orders of magnitude less than that of vector-only control (2.6 × 104/µg DNA), suggesting inhibition associated with the cloned phage DNA. Of these clones, four from the BglII library and three from the PstI library were selected for further study. Where possible, regions of DNA with no apparent contribution to the inhibitory phenotype were removed by restriction digestion and subcloning, although in some cases the phenotype was not narrowed down to a single open reading frame (ORF). Following sequencing of these DNA (from ten subclones in total), 13 ORFs were predicted to possess a R. equi inhibition phenotype. Moreover, ten of these did not possess similarities that enabled function prediction using BLASTn against the nucleotide collection database or BLASTx against the non-redundant protein sequence database (Table 1). A myriad of novel bactericidal or bacteriostatic activities may be associated with products encoded by these genes with unknown functions, and the focus of future studies should be to search for their respective cellular targets. When the predicted phage protein sequences were searched for functional domains, repeats, or signatures against the InterPro database (, the only predictions that could be made were transmembrane domains in clones pYF1B7A and pYF1B19A. It is difficult to assume their function from these data alone.

Table thumbnail
Table 1. Summary of YF1 DNA inhibiting R. equi

It is important to note a few points here. None of the clones in this study are inhibitory against E. coli, as the library was constructed in this host. This means either that the activities of the products encoded by the clones are specific toward Rhodococcus or potentially other closely-related Gram-positive bacteria, or that those genes were simply not expressed in E. coli. Flanking the polylinker on one end in pDA71, the phage λ PR promoter drives expression of cloned genes in E. coli. This promoter probably functions sub-optimally in Rhodococcus; even if it did drive transcription in this host, we expect its level to be low. No known promoter exits on the opposite side of the polylinker. As the phage DNA fragments were ligated into the vector in either one of two possible orientations, most of expression of these phage genes in Rhodococcus were probably off their native phage promoters. It is also important to caution that not all of these genes may necessarily encode products which are designed to inactivate or modify essential cellular enzymes during phage infection. For example, the thymidylate synthase complementing protein,8 which is potentially encoded by one of the inhibitory YF1 genes (Table 1), may simply be interfering with the balance of cellular enzymes in the pathway for thymidine production. Nucleotide production (specifically, folate biosynthesis), however, is a well-known pathway which is targeted by the sulphonamide class of antibiotics and may represent a weakness in bacteria. Coincidentally, the thymidylate synthase complementing protein has been investigated as a drug target as its distribution is limited mainly within eubacteria and archaea.9

Spread of multidrug resistance in pathogenic bacteria has not been countered by the discovery and development of new classes of antibiotics. As natural killers of bacteria, phages have the potential to make important contributions in several ways: 1) through phage therapy using phage particles as therapeutic agents,10 2) through the use of phage lysins or other phage-encoded bacterial killing agents,11 and 3) indirectly, through the use of phage to identify cellular components targeted by phage proteins that have the potential to serve as targets for antimicrobial design. Each of these options relies on the abundance and diversity of phages in nature; for identification of novel targets, it is also desirable that multiple targets be identified from a single virus. Although only a small portion of the identified YF1 genes may encode products that specifically target indispensable host components, our work shows that a mere single phage that was readily isolated from the environment, possessing a relatively small genome of 55kb, contains a wealth of genes that are inhibitory upon introduction into a bacterial host. Genomes of phages for any pathogen of interest may be screened in a similar fashion. These may include methicillin-resistant S. aureus and multidrug-resistant Streptococcus pneumoniae, Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Klebsiella pneumoniae to name a few pathogens whose global spread is a major threat to human health. To continue this phage-mediated approach by identifying cellular targets and small molecules with similar activities is not a trivial task. As Liu et al.2 have shown, these involve various biochemical assays and a high-throughput screening of chemical libraries. Given its potential, however, this approach is one that could be pursued if we are to turn around what seems to be a losing battle against superbugs.


This work was supported by the National Research Foundation and the Medical Research Council of South Africa.



Acquired Immune Deficiency Syndrome
open reading frame


1. Sau S, Chattoraj P, Ganguly T, Chanda PK, Mandal NC. Inactivation of indispensable bacterial proteins by early proteins of bacteriophages: implication in antibacterial drug discovery. Curr Protein Pept Sci. 2008;9:284–90. doi: 10.2174/138920308784533970. [PubMed] [Cross Ref]
2. Liu J, Dehbi M, Moeck G, Arhin F, Bauda P, Bergeron D, et al. Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol. 2004;22:185–91. doi: 10.1038/nbt932. [PubMed] [Cross Ref]
3. Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011;1:31–45. doi: 10.4161/bact.1.1.14942. [PMC free article] [PubMed] [Cross Ref]
4. von Bargen K, Haas A. Molecular and infection biology of the horse pathogen Rhodococcus equi. FEMS Microbiol Rev. 2009;33:870–91. doi: 10.1111/j.1574-6976.2009.00181.x. [PubMed] [Cross Ref]
5. Corti M, Palmero D, Eiguchi K. Respiratory infections in immunocompromized patients. Curr Opin Pulm Med. 2009;15:209–17. doi: 10.1097/MCP.0b013e328329bd2c. [PubMed] [Cross Ref]
6. Quan S, Dabbs ER. Nocardioform arsenic resistance plasmid characterization and improved Rhodococcus cloning vectors. Plasmid. 1993;29:74–9. doi: 10.1006/plas.1993.1010. [PubMed] [Cross Ref]
7. Clarke L, Carbon J. A colony bank containing synthetic Col El hybrid plasmids representative of the entire E. coli genome. Cell. 1976;9:91–9. doi: 10.1016/0092-8674(76)90055-6. [PubMed] [Cross Ref]
8. Myllykallio H, Lipowski G, Leduc D, Filee J, Forterre P, Liebl U. An alternative flavin-dependent mechanism for thymidylate synthesis. Science. 2002;297:105–7. doi: 10.1126/science.1072113. [PubMed] [Cross Ref]
9. Mathews II, Deacon AM, Canaves JM, McMullan D, Lesley SA, Agarwalla S, et al. Functional analysis of substrate and cofactor complex structures of a thymidylate synthase-complementing protein. Structure. 2003;11:677–90. doi: 10.1016/S0969-2126(03)00097-2. [PubMed] [Cross Ref]
10. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1:66–85. doi: 10.4161/bact.1.2.15845. [PMC free article] [PubMed] [Cross Ref]
11. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents. 2007;30:118–28. doi: 10.1016/j.ijantimicag.2007.04.006. [PubMed] [Cross Ref]

Articles from Bacteriophage are provided here courtesy of Taylor & Francis